CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/06/23
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023GlobeNewsWire • 11/06/23
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 11/03/23
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDAThe Motley Fool • 11/03/23
CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 11/02/23
Wall Street Analysts See a 108.46% Upside in CRISPR Therapeutics AG (CRSP): Can the Stock Really Move This High?Zacks Investment Research • 11/02/23
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?The Motley Fool • 11/02/23
CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?Zacks Investment Research • 11/02/23
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing DrugInvestors Business Daily • 11/01/23
Crispr Therapeutics' stock soars premarket after positive meeting of FDA panel on sickle-cell disease therapyMarket Watch • 11/01/23
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up studyReuters • 10/31/23
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell DiseaseGlobeNewsWire • 10/31/23
Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/31/23
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)GlobeNewsWire • 10/31/23
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain PatientThe Motley Fool • 10/30/23
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene TherapyInvestorPlace • 10/27/23